Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

• Status: Withdrawn
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma

Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment